The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.

The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options. A third of cancer vaccines in development are now oncolytic viruses, which are being developed for about 40 different types of cancer. In Vivo takes a closer look at therapies in development to see what the future holds for this promising therapy.

LASIK continues to hold a dominant share of the refractive surgical market but limitations in current technologies are stymying further growth. However, a tide of innovation refractive correction is coming in now, and over the next few years that will accelerate growth in this market and fully capitalize on this huge and yet undertapped opportunity known as presbyopia. This article discusses drivers and barriers in the refractive correction market and highlights three companies to look out for this space.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.